Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid H Olsen; Jens B Sørensen; Birgitte Federspiel; Andreas Kjaer; Carsten P Hansen; Ulrich Knigge; Seppo W Langer

doi:10.1100/2012/170496

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Ingrid H Olsen
, Jens B Sørensen
, Birgitte Federspiel
, Andreas Kjaer
, Carsten P Hansen
, Ulrich Knigge
, Seppo W Langer

71 Citations (Scopus)

Abstract

Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

Original language	English
Journal	Scientific World Journal
Volume	2012
Pages (from-to)	170496
Number of pages	4
ISSN	1537-744X
DOIs	https://doi.org/10.1100/2012/170496
Publication status	Published - 2012

Access to Document

10.1100/2012/170496

Cite this

@article{411451f9de8943c48f722757e9c994a1,

title = "Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas",

abstract = "Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.",

author = "Olsen, \{Ingrid H\} and S{\o}rensen, \{Jens B\} and Birgitte Federspiel and Andreas Kjaer and Hansen, \{Carsten P\} and Ulrich Knigge and Langer, \{Seppo W\}",

year = "2012",

doi = "10.1100/2012/170496",

language = "English",

volume = "2012",

pages = "170496",

journal = "Scientific World Journal",

issn = "1537-744X",

publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

AU - Olsen, Ingrid H

AU - Sørensen, Jens B

AU - Federspiel, Birgitte

AU - Kjaer, Andreas

AU - Hansen, Carsten P

AU - Knigge, Ulrich

AU - Langer, Seppo W

PY - 2012

Y1 - 2012

N2 - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

AB - Knowledge of the clinical efficacy in recurrent neuroendocrine carcinomas is sparse. Treatment with temozolomide alone or in combination with capecitabine and bevacizumab has recently shown promising results.

U2 - 10.1100/2012/170496

DO - 10.1100/2012/170496

M3 - Journal article

C2 - 22973169

SN - 1537-744X

VL - 2012

SP - 170496

JO - Scientific World Journal

JF - Scientific World Journal

ER -

Temozolomide as second or third line treatment of patients with neuroendocrine carcinomas

Abstract

Access to Document

Fingerprint

Cite this